Co-administration may reduce divalproex sodium concentrations below therapeutic range, increasing risk of breakthrough seizures, similar to valproic acid interaction.
Source: NLP:meropenem-vaborbactam
Meropenem And Sodium Chloride Interactions
Brand names: Meropenem And Sodium Chloride
beta Lactamase Inhibitor · beta Lactamase Inhibitors
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Meropenem for Injection and Sodium Chloride Injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. Known hypersensitivity to product components or anaphylactic reactions to beta-lactams. ( 4 ) Contraindicated where the administration of sodium or chloride could be clinically detrimental. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women. No fetal toxicity or malformations were observed in pregnant rats and cynomolgus macaques administered intravenous meropenem during organogenesis at doses up to 3.2 and 2.3 times the maximum recommended human dose based on body surface area comparison, respectively. In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the maximum recommended human dose based on body surface area comparison [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Reproductive studies have been performed with meropenem in rats at doses of up to 1000 mg/kg/day and in cynomolgus monkeys at doses of up to 360 mg/kg/day (on the basis of body surface area comparisons, approximately 3.2 times and 2.3 times higher, respectively, than the maximum recommended human dose of 1 gram every 8 hours). These studies revealed no evidence of harm to the fetus due to meropenem, although there were slight changes in fetal body weight at doses of 250 mg/kg/day (equivalent to approximately 0.8 times the maximum recommended human dose of 1 gram every 8 hours based on body surface area comparison) and above in rats. In a published study 2 , meropenem administered to pregnant rats from Gestation Day 6 to Gestation Day 17, was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity. The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/
4 interactions on record
Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Coadministration is not recommended.
Source: NLP:meropenem and sodium chloride
Co-administration may reduce valproic acid concentrations below therapeutic range, increasing risk of breakthrough seizures. Mechanism may involve carbapenem inhibition of valproic acid glucuronide metabolite hydrolysis.
Source: NLP:meropenem-vaborbactam
Effectiveness may be reduced due to metabolism via CYP3A and PXR-regulated enzymes. Effective alternative non-hormonal forms of contraception or additional contraceptive methods are recommended.
Source: NLP:meropenem-vaborbactam